Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection

Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1) antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, the most common form of HIV.1.

 

Comments:

That's correct! Cabotegravir, also known by its brand name Apretude, is an extended-release injectable medication used as pre-exposure prophylaxis (PrEP) for HIV-1. It belongs to the class of antiretroviral drugs called integrase strand transfer inhibitors (INSTIs).

Cabotegravir is specifically indicated for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative but at high risk of acquiring HIV-1 through sexual contact. It is designed to reduce the risk of sexually acquired HIV-1 infection when used consistently and correctly.

The extended-release formulation of cabotegravir allows for longer dosing intervals, with injections typically administered once every 4 or 8 weeks, depending on the specific treatment regimen. This makes it a convenient option for individuals who may have difficulty adhering to daily oral PrEP medications.

It's important to note that cabotegravir should always be used in combination with a comprehensive prevention approach, including safe sex practices and regular HIV testing. It is essential to consult with a healthcare professional for proper evaluation and guidance regarding the use of cabotegravir as PrEP.

Related Products

Cat.No.	Product Name	Information
S7766	Cabotegravir (GSK1265744)	Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.

Related Targets

Integrase